MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.04
-1.79
-9.51%
After Hours: 17.10 +0.06 +0.35% 18:39 01/17 EST
OPEN
18.44
PREV CLOSE
18.83
HIGH
18.89
LOW
16.98
VOLUME
2.61M
TURNOVER
--
52 WEEK HIGH
20.09
52 WEEK LOW
3.920
MARKET CAP
1.07B
P/E (TTM)
-4.9777
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KPTI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KPTI News

  • Benzinga's Top Upgrades, Downgrades For January 17, 2020
  • Benzinga.2d ago
  • Wedbush Downgrades Karyopharm Therapeutics to Neutral
  • Benzinga.2d ago
  • BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
  • Zacks.4d ago
  • H.C. Wainwright Reiterates Buy on Karyopharm Therapeutics, Raises Price Target to $37
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About KPTI

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More

Webull offers Karyopharm Therapeutics Inc (KPTI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.